{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:58:22Z","timestamp":1790801902185,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["202540010"],"award-info":[{"award-number":["202540010"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020732","name":"Innovative Research Team of High-level Local Universities in Shanghai","doi-asserted-by":"publisher","award":["SHSMU-ZDCX20211002"],"award-info":[{"award-number":["SHSMU-ZDCX20211002"]}],"id":[{"id":"10.13039\/100020732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371799"],"award-info":[{"award-number":["82371799"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271820"],"award-info":[{"award-number":["82271820"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ard.2026.08.017","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:33:04Z","timestamp":1790595184000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["BAFF-APRIL blockade reveals isotype-specific pathogenic autoantibody remodelling in antiphospholipid syndrome"],"prefix":"10.1016","author":[{"given":"Haoyu","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengde","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3574-8807","authenticated-orcid":false,"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ard.2026.08.017_bib0001","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/art.43258","article-title":"Antiphospholipid syndrome: an antibody-mediated disease with emerging therapeutic opportunities","volume":"77","author":"Newman","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ard.2026.08.017_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102212","article-title":"Treatment advances in antiphospholipid syndrome: 2022 update","volume":"65","author":"Erton","year":"2022","journal-title":"Curr Opin Pharmacol."},{"key":"10.1016\/j.ard.2026.08.017_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1523392","article-title":"Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sj\u00f6gren's syndrome","volume":"16","author":"Poznyak","year":"2025","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.ard.2026.08.017_bib0004","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med."},{"issue":"6","key":"10.1016\/j.ard.2026.08.017_bib0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41584-024-01110-y","article-title":"Rethinking antiphospholipid syndrome to guide future management and research","volume":"20","author":"Knight","year":"2024","journal-title":"Nat Rev Rheumatol."},{"issue":"10","key":"10.1016\/j.ard.2026.08.017_bib0006","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"18","key":"10.1016\/j.ard.2026.08.017_bib0007","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.125.073552","article-title":"Microvascular endothelial cells license APS vasculopathy through YAP1- and CCN2-mediated signaling","volume":"152","author":"Shi","year":"2025","journal-title":"Circulation."},{"issue":"12","key":"10.1016\/j.ard.2026.08.017_bib0008","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.2023022097","article-title":"Low ectonucleotidase activity and increased neutrophil-platelet aggregates in patients with antiphospholipid syndrome","volume":"143","author":"NaveenKumar","year":"2024","journal-title":"Blood."},{"key":"10.1016\/j.ard.2026.08.017_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109714","article-title":"Interaction of the antiphospholipid syndrome autoantigen beta-2 glycoprotein I with DNA and neutrophil extracellular traps","volume":"255","author":"Kmetova","year":"2023","journal-title":"Clin Immunol."},{"key":"10.1016\/j.ard.2026.08.017_bib0010","article-title":"Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.ard.2026.08.017_bib0011","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2016.06.026","article-title":"Antiphospholipid syndrome and kidney disease","volume":"91","author":"Bienaime","year":"2017","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.ard.2026.08.017_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102798","article-title":"B cells in primary antiphospholipid syndrome: Review and remaining challenges","volume":"20","author":"Dieudonn\u00e9","year":"2021","journal-title":"Autoimmun Rev."},{"issue":"1","key":"10.1016\/j.ard.2026.08.017_bib0013","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/jcm12010018","article-title":"B-Cells and BAFF in primary antiphospholipid syndrome, targets for therapy?","volume":"12","author":"van den Hoogen","year":"2022","journal-title":"J Clin Med."},{"issue":"2","key":"10.1016\/j.ard.2026.08.017_bib0014","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ard.2026.08.017_bib0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.55563\/clinexprheumatol\/cc5taf","article-title":"Rituximab for refractory manifestations of the antiphospholipid syndrome: a multicentre Israeli experience","volume":"39","author":"Agmon-Levin","year":"2021","journal-title":"Clin Exp Rheumatol."},{"issue":"12","key":"10.1016\/j.ard.2026.08.017_bib0016","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1177\/09612033221122147","article-title":"The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome","volume":"31","author":"Sayar","year":"2022","journal-title":"Lupus."},{"key":"10.1016\/j.ard.2026.08.017_bib0017","first-page":"597","article-title":"Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and\/or non-criteria manifestations of antiphospholipid syndrome: study protocol","volume":"41","author":"Sciascia","year":"2023","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.ard.2026.08.017_bib0018","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol."},{"issue":"14","key":"10.1016\/j.ard.2026.08.017_bib0019","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs."},{"key":"10.1016\/j.ard.2026.08.017_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105704","article-title":"Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS\/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis","volume":"159","author":"Yao","year":"2021","journal-title":"Eur J Pharm Sci."},{"key":"10.1016\/j.ard.2026.08.017_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J Autoimmun."},{"issue":"2","key":"10.1016\/j.ard.2026.08.017_bib0022","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost."},{"issue":"11","key":"10.1016\/j.ard.2026.08.017_bib0023","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.ard.2026.08.017_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.12688\/f1000research.22139.1","article-title":"scRepertoire: an R-based toolkit for single-cell immune receptor analysis","volume":"9","author":"Borcherding","year":"2020","journal-title":"F1000Res."},{"issue":"11","key":"10.1016\/j.ard.2026.08.017_bib0025","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/s41590-022-01345-5","article-title":"Heterogeneous plasma cells and long-lived subsets in response to immunization, autoantigen and microbiota","volume":"23","author":"Liu","year":"2022","journal-title":"Nat Immunol."},{"issue":"7","key":"10.1016\/j.ard.2026.08.017_bib0026","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41577-024-00991-0","article-title":"New insights into the ontogeny, diversity, maturation and survival of long-lived plasma cells","volume":"24","author":"Fooksman","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ard.2026.08.017_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2024.102442","article-title":"New insights into the mechanisms regulating plasma cell survival and longevity","volume":"88","author":"Khamyath","year":"2024","journal-title":"Curr Opin Immunol."},{"issue":"25","key":"10.1016\/j.ard.2026.08.017_bib0028","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121260119","article-title":"Isotype-specific plasma cells express divergent transcriptional programs","volume":"119","author":"Higgins","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.ard.2026.08.017_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112682","article-title":"Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses","volume":"42","author":"Duan","year":"2023","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.ard.2026.08.017_bib0030","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol."},{"issue":"6638","key":"10.1016\/j.ard.2026.08.017_bib0031","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/40540","article-title":"Lifetime of plasma cells in the bone marrow","volume":"388","author":"Manz","year":"1997","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ard.2026.08.017_bib0032","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol."},{"issue":"7","key":"10.1016\/j.ard.2026.08.017_bib0033","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/jth.14492","article-title":"Commentary on: circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation","volume":"17","author":"Yin","year":"2019","journal-title":"J Thromb Haemost."},{"issue":"1","key":"10.1016\/j.ard.2026.08.017_bib0034","doi-asserted-by":"crossref","first-page":"9921","DOI":"10.1038\/s41467-024-54228-8","article-title":"Defective germinal center selection results in persistence of self-reactive B cells from the primary to the secondary repertoire in Primary Antiphospholipid Syndrome","volume":"15","author":"Dieudonne","year":"2024","journal-title":"Nat Commun."},{"issue":"3","key":"10.1016\/j.ard.2026.08.017_bib0035","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","article-title":"Humoral immunity due to long-lived plasma cells","volume":"8","author":"Slifka","year":"1998","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ard.2026.08.017_bib0036","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2011-03-344671","article-title":"A novel pathway for human endothelial cell activation by antiphospholipid\/anti-beta2 glycoprotein I antibodies","volume":"119","author":"Allen","year":"2012","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.ard.2026.08.017_bib0037","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"3","key":"10.1016\/j.ard.2026.08.017_bib0038","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/art.39938","article-title":"In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis","volume":"69","author":"Meng","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.ard.2026.08.017_bib0039","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ard.2026.08.017_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102978","article-title":"Whole blood transcriptome identifies interferon-regulated genes as key drivers in thrombotic primary antiphospholipid syndrome","volume":"134","author":"Verrou","year":"2023","journal-title":"J Autoimmun."},{"issue":"11","key":"10.1016\/j.ard.2026.08.017_bib0041","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","article-title":"A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.ard.2026.08.017_bib0042","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672600542X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672600542X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:54:49Z","timestamp":1790798089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672600542X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"alternative-id":["S000349672600542X"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.08.017","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BAFF-APRIL blockade reveals isotype-specific pathogenic autoantibody remodelling in antiphospholipid syndrome","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}